Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US81749D1072
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG001J19ZJ7
SERA
Sera Prognostics Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Diagnostics & Research · THEMEFOLIO: $HLTH
NAME
Sera Prognostics Inc
ISIN
US81749D1072
TICKER
SERA
MIC
XNAS
REUTERS
SERA.OQ
BLOOMBERG
SERA US
Di., 23.06.2026       Sera Prognostics
US81749D1072

--Aligns With Growing Focus on Early Identification and Management of Preterm Birth Risk--SALT LAKE CITY, June 23, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information, today acknowledged recent legislative action...
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Mo., 01.06.2026       Sera Prognostics
US81749D1072

SALT LAKE CITY, June 1, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott has notified the Company of his intention to step down from its Board of Dire...
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Mi., 06.05.2026       Sera Prognostics
US81749D1072

SALT LAKE CITY, May 6, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter ended March 31, 2026....
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Mi., 22.04.2026       Sera Prognostics
US81749D1072

SALT LAKE CITY, April 22, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report first quarter fiscal year 2026 financial results on Wednesday May 6, 2026, aft...
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Mi., 18.03.2026       Sera Prognostics
US81749D1072

SALT LAKE CITY, March 18, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2025....
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Mi., 04.03.2026       Sera Prognostics
US81749D1072

SALT LAKE CITY, March 4, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report fourth quarter and fiscal year 2025 financial results on Wednesday March 18, 20...
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Di., 17.02.2026       Sera Prognostics
US81749D1072

SALT LAKE CITY, Feb. 17, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the TD Cowen 46th Annual Health Care Conference on Monday, Ma...
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Mi., 07.01.2026       Sera Prognostics
US81749D1072

Published in the journal PREGNANCY, the PRIME Study demonstrates significant improvements in neonatal outcomes with early risk screening and targeted interventions.SALT LAKE CITY, Jan. 7, 2026 /PRNewswire/ -- A randomized controlled trial of 5,018 women has found that a simple blood test, when paired with targeted interventions, can significantly...
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Mo., 24.11.2025       Sera Prognostics
US81749D1072

The PRIME study, one of the largest studies on preterm birth, has been accepted for publication by a medical journal following abstract presentation earlier this yearSALT LAKE CITY, Nov. 24, 2025 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative...
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Do., 13.11.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY, Nov. 13, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2025 ended Septe...
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 30.10.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY, Oct. 30, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report third quarter fiscal year 2025 financial res...
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Mi., 01.10.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY, Oct. 1, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker testing to help deliver information to doctors and patients, today announced the appointment of Tiffany Inglis, M...
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Do., 28.08.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY, Aug. 28, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the H.C. Wainwright 27th Annual Global Investment Conference...
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Di., 29.07.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY, July 29, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report second quarter fiscal year 2025 financial results on Wednesday, August 6,...
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Do., 29.05.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY, May 29, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that members of the Sera team will participate in the following upcoming investor conferences:...
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Mi., 14.05.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY , May 14, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the RBC Global Healthcare Conference on Wednesday, May 21, 2...
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Do., 08.05.2025       Sera Prognostics
US81749D1072

Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announce...
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Mi., 07.05.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY, May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2025 ended March 31, 2025....
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Do., 24.04.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY, April 24, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first quarter fiscal year 2025 financial results on Wednesday, May 7, 20...
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Mi., 19.03.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further an...
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mi., 19.03.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2024....
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Di., 11.03.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY, March 11, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, March...
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Fr., 21.02.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY, Feb. 21, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the TD Cowen 45th Annual Health Care Conference on Wednesday...
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Di., 11.02.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY, Feb. 10, 2025 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® ("Sera" or the "Company") (Nasdaq: SERA), which focuses on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the pricing of its underwritten public offering of 1,250,000...
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Mo., 10.02.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY, Feb. 10, 2025 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® ("Sera" or the "Company") (Nasdaq: SERA), which focuses on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it has commenced a proposed underwritten public offerin...
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Mo., 27.01.2025       Sera Prognostics
US81749D1072

Event will showcase results of Company's pivotal PRIME study and include the principal investigator SALT LAKE CITY, Jan. 27, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today ann...
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Mo., 06.01.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY, Jan. 6, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference taking plac...
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Mi., 04.12.2024       Sera Prognostics
US81749D1072

SALT LAKE CITY, Dec. 4, 2024 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the results of the PRIME study were accepted as a late-breaking abstract for oral podium...
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Mo., 02.12.2024       Sera Prognostics
US81749D1072

SALT LAKE CITY, Dec. 2, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the Piper Sandler 36th Annual Healthcare Conference on Decemb...
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Fr., 15.11.2024       Sera Prognostics
US81749D1072

SALT LAKE CITY, Nov. 15, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the Canaccord Genuity MedTech, Diagnostics and Digital Healt...
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Mi., 06.11.2024       Sera Prognostics
US81749D1072

SALT LAKE CITY, Nov. 6, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2024 ended September 30, 2024....
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Mo., 28.10.2024       Sera Prognostics
US81749D1072

SALT LAKE CITY, Oct. 28, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report third quarter fiscal year 2024 financial results on Wednesday, November 6...
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Mi., 04.09.2024       Sera Prognostics
US81749D1072

SALT LAKE CITY, Sept. 4, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the H.C. Wainwright Global Investment Conference on Wednesda...
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink
Do., 08.08.2024       Sera Prognostics
US81749D1072

SALT LAKE CITY, Aug. 8, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that its management team will participate in the following upcoming investor conference: ...
Zur Nachricht
Sera Prognostics
Charts & Research Termsheets Terminal
Permalink